PHARMACOKINETICS OF CONCOMITANTLY ADMINISTERED FOSCARNET AND ZIDOVUDINE FOR TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (AIDS CLINICAL-TRIALS GROUP PROTOCOL-053)

被引：15
|
作者：
AWEEKA, FT
GAMBERTOGLIO, JG
VANDERHORST, C
RAASCH, R
JACOBSON, MA
机构：
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143
[2] UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599
[3] UNIV N CAROLINA,SCH PHARM,CHAPEL HILL,NC 27599
[4] SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1992年 / 36卷 / 08期
关键词：
D O I：
10.1128/AAC.36.8.1773
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.
引用
收藏
页码：1773 / 1778
页数：6
相关论文
共 50 条
  • [41] The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    Eron, JJ
    Smeaton, LM
    Fiscus, SA
    Gulick, RM
    Currier, JS
    Lennox, JL
    D'Aquila, RT
    Rogers, MD
    Tung, R
    Murphy, RL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05): : 1622 - 1628
  • [42] NEUTRALIZING ANTIBODY-ACTIVITY IN SERA FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE RECIPIENTS FROM THE AIDS VACCINE CLINICAL-TRIALS NETWORK
    MASCOLA, J
    WEISLOW, O
    SNYDER, S
    BELAY, S
    YEAGER, M
    MCCUTCHAN, F
    MCNEIL, J
    BURKE, D
    WALKER, MC
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S55 - S55
  • [43] CLINICAL PICTURE AND TREATMENT OF HERPETIC INJURIES TO THE EYE DURING INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)
    KASPAROV, AA
    MARCHENKO, NR
    [J]. VESTNIK OFTALMOLOGII, 1994, 110 (04) : 35 - 37
  • [44] PREVALENCE AND CLINICAL-SIGNIFICANCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATED FROM PATIENTS AFTER LONG-TERM ZIDOVUDINE TREATMENT
    JAPOUR, AJ
    WELLES, S
    DAQUILA, RT
    JOHNSON, VA
    RICHMAN, DD
    COOMBS, RW
    REICHELDERFER, PS
    KAHN, JO
    CRUMPACKER, CS
    KURITZKES, DR
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05): : 1172 - 1179
  • [45] EVALUATING THE ROLE OF CD4-LYMPHOCYTE COUNTS AS SURROGATE END-POINTS IN HUMAN-IMMUNODEFICIENCY-VIRUS CLINICAL-TRIALS
    LIN, DY
    FISCHL, MA
    SCHOENFELD, DA
    [J]. STATISTICS IN MEDICINE, 1993, 12 (09) : 835 - 842
  • [46] EVALUATING THE ROLE OF CD4-LYMPHOCYTE COUNTS AS SURROGATE END-POINTS IN HUMAN-IMMUNODEFICIENCY-VIRUS CLINICAL-TRIALS
    LIN, DY
    FISCHL, MA
    SCHOERFELD, DA
    [J]. STATISTICS IN MEDICINE, 1994, 13 (18) : 1895 - 1896
  • [47] ZIDOVUDINE (AZT) FOR TREATMENT OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - AN EVALUATION OF EFFECTIVENESS IN CLINICAL-PRACTICE
    COLSON, ER
    HORWITZ, RI
    BIA, FJ
    VISCOLI, CM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (04) : 709 - 713
  • [48] TOXIC EFFECTS OF ZIDOVUDINE IN ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS WITH CD4+ CELL COUNTS OF 0.50X109/L OR LESS - DETAILED AND UPDATED RESULTS FROM PROTOCOL-019 OF THE AIDS CLINICAL-TRIALS GROUP
    KOCH, MA
    VOLBERDING, PA
    LAGAKOS, SW
    BOOTH, DK
    PETTINELLI, C
    MYERS, MW
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (11) : 2286 - 2292
  • [49] AIDS CLINICAL-TRIALS GROUP - PHASE-I/II STUDY OF COMBINATION 2',3'-DIDEOXYCYTIDINE AND ZIDOVUDINE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) AND ADVANCED AIDS-RELATED COMPLEX
    MENG, TC
    FISCHL, MA
    RICHMAN, DD
    [J]. AMERICAN JOURNAL OF MEDICINE, 1990, 88 (5B): : S27 - S30
  • [50] A CONTROLLED TRIAL OF EARLY VERSUS LATE TREATMENT WITH ZIDOVUDINE IN SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - RESULTS OF THE VETERANS AFFAIRS COOPERATIVE STUDY
    HAMILTON, JD
    HARTIGAN, PM
    SIMBERKOFF, MS
    DAY, PL
    DIAMOND, GR
    DICKINSON, GM
    DRUSANO, GL
    EGORIN, MJ
    GEORGE, WL
    GORDIN, FM
    HAWKES, CA
    JENSEN, PC
    KLIMAS, NG
    LABRIOLA, AM
    LAHART, CJ
    OBRIEN, WA
    OSTER, CN
    WEINHOLD, KJ
    WRAY, NP
    ZOLLAPAZNER, SB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (07): : 437 - 443
12345